用Cyfra21-1检测血中细胞角质素片断CKS-19在肺癌诊断中的意义

Use of Cyfra21-1 in the Diagnosis of Lung Cancer

用酶联免疫方法，试剂Cyfra21－1，测定42例健康人，23便非肿瘤性肺部疾病病人，68例肺癌病人血清中的细胞角质素片断CKS－19。健康人为1．45±0．86ng／ml，非肿瘤性肺疾病病人为1．64±1．40ng／ml。肺癌中鳞癌16例，腺癌33例，小细胞肺癌19例，Cyfra21－1阳性率各为75．0％，66．7／，31．6％。比较Cyfra21－1和CEA，NSE三种肺癌标志物的ROC曲线，Cyfra21－1的曲线最接近左上角，证明Cyfra21－1是敏感性，特异性较好的肺癌标志物。

The serum CKS-19 of 42 healthy persons, 23 patients with various benign diseases and 68 patients with hlstologlcally proven lung cancer were determined by using Cyfra21-1 and was evaluated with the results of CEA and NSF. It was shown that Cyfra21-1 yielded the highest sensitivity in lung cancer group as a whole (66. 2 % ) and that the positive rates of squamous cell carcinoma and adeno carclnoma were 75. 0%, 66. 2% resPectively, however, small cell carcinoma gave lower value (31. 6% ) of Cyfra21-1 than NSE (35- 5 % ).On the ROC curve that of the Cyfra21-1 inclined toward the leftAnupper quadrant than those of CEA and NSE indicating its higher sensitivity and specificity.